This bulletin describes the awareness of naloxone and the take-home naloxone program in Australia, both nationally and by jurisdiction. It also explores access, use and acceptance of naloxone, and examines demographic differences for these aspects (NDARC)
Archives for May 2020
Bibliography: All Publications
Drug-related infectious diseases in Europe: Update from the EMCDDA expert network, 2020
This 2020 EMCDDA update on drug-related infectious diseases aims to provide a comprehensive overview of the current situation with regard to the epidemiological picture of drug-related infectious diseases in Europe up to January 2020, while highlighting some of the current innovative responses to the problem
Adulterants, Contaminants and Co-occurring Substances in Drugs on the Illegal Market in Canada
Provides a snapshot of the contents of drugs on the illegal market in Canada using 2018–2019 data from drug seizures, drug checking services and a drug monitoring study. This bulletin is accompanied by a technical report featuring detailed research methods and data PDF (CCENDU )
Synthetic Drugs in East and Southeast Asia (PDF)
Latest developments and challenges (UNODC)
NODC report on East and Southeast Asia
Continued growth in the supply of methamphetamine while synthetic opioids spread – Download (UNODC)
The Uruguay – West Africa trafficking connection. An urgent need for closer cooperation and policy exchange (PDF)
Uruguay’s emergence as a transit route for cocaine provides new challenges to international law enforcement cooperation and creates greater need for setting up secure channels of communication between Uruguayan and West African law enforcement (Gdpo)
COVID-19: guidance for commissioners and providers of services for people who use drugs or alcohol
This guidance outlines COVID-19 advice for commissioners and service providers involved in assisting people who are dependent on drugs or alcohol or both (PHE)
COVID-19 and the drug supply chain: from production and trafficking to use (PDF)
Based on the most recent data from government authorities, open sources, including the media, and the network of UNODC field offices, the evidence available suggests the following ongoing dynamics in the impact of the COVID-19 pandemic on the illicit drug markets (RAND)
Assessing the Evidence on Supervised Drug Consumption Sites
This working paper assesses evidence on and arguments made about supervised consumption sites (RAND)
Family Drug and Alcohol Courts under Covid-19: A Practice Briefing
This briefing examines how the nine existing FDACs across England are adapting to service delivery during the current crisis. It highlights the practical challenges facing practitioners, judges and families, and shines a light on specific solutions that have been developed in response to the Covid-19 pandemic (Centre for Justice Innovation)
COVID-19 is changing the route of illicit drug flows, says UNODC report
UNODC has collected data from government authorities, UNODC field offices, open sources, and information from media that are now summarized in the COVID-19 and DrugMarkets report
Summary of monitoring of cryptomarkets for drug listings, 1 February 2014 – 31 January 2020
This summary reports on trends in the availability and type of substances sold on the internet via cryptomarkets from 1 February 2014 to 31 January 2020 (NDARC)
EMCDDA special report: COVID-19 and drugs – Drug supply via darknet markets
This report is a rapid and preliminary analysis of the impact of COVID-19 on selected online markets (EMCDDA)
Clinical guidelines for use of depot buprenorphine (Buvidal® ) in the treatment of opioid dependence (PDF)
This Clinical Guideline has been developed to inform decision-making by clinicians prescribing and/or patients being treated with Buvidal® long-acting injected buprenorphine preparations (SMMGP)
Safety of low dose cannabidiol
The review identified that there were potential conditions for low dose cannabidiol that would not require oversight by a medical practitioner. (Australian Government)